What if everyone could get a test?
The earlier cancer is detected, the easier it is to fight. Knowing your risk early means knowing you’ll be alright.
Anpac Bio was founded in 2010 by a diverse team with backgrounds in medicine and biotechnology. Since beginning our cancer screening service in China in 2015, we have established blood databases with over 200,000 samples.
Cancer Research & Detection
Chemistry & Bio-chemistry
Nano-technology & Physics
Surface & Material Science
Engineering & Manufacturing
Co-Founders Dr. Chris Yu and Dr. Herbert Yu brought together an integrated R&D team from China and the U.S. and tasked them with combining their expertise in mechatronics, physics, biomedical science and computer science to create our innovative, patented early cancer screening and detection technology.
Our patented Cancer Differentiation Analysis (CDA) technology requires only a standard blood sample from a tested individual to conduct an early cancer screening and detection test, with no harmful side effects in patients.
*As of June 30, 2020
Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.Read the full article